The phase III studies SPOTLIGHT (NCT03504397) were designed as potential registration trials to assess the advantages of adding zolbetuximab to chemotherapy (either mFOLFOX6 or capecitabine and oxaliplatin (CAPOX)) in previously untreated patients with recurrent or metastatic HER-2-negative, CLDN18.2-positive G/GEJ cancer, defined as having moderate to strong CLDN18.2 expression in 75% or more of tumour cells [11]. In the SPOTLIGHT trial, 565 patients from 215 centers were enrolled and randomly assigned (1:1) to either zolbetuximab plus mFOLFOX6 or placebo plus mFOLFOX6. Here, ERBB2 is linked to neoplasm.